Drugs & Targets FDA grants priority review to Lonsurf + Avastin for refractory metastatic CRC April 21, 2023Vol.49 No.16
Drugs & Targets Purdue Ventures invests in antibody-based cancer therapeutics company April 21, 2023Vol.49 No.16
Trials & Tribulations San Antonio Breast Cancer Symposium 2022 tackled big obstacles, recommended solutions for breast cancer progress April 14, 2023Vol.49 No.15By Angela DeMichele, Rajarshi Sengupta and Carlos L. Arteaga
Guest Editorial Mifepristone and the Administrative Procedure Act: Perspective of a former FDA commissioner and NCI director April 14, 2023Vol.49 No.15By Norman E. "Ned" Sharpless
Pragmatica-Lung, a landmark pragmatic trial with registrational intent, starts enrollment April 14, 2023Vol.49 No.15By Jacquelyn Cobb
In Brief Georgetown’s Lombardi CCC to open Ralph Lauren Center for Cancer Prevention in Washington, DC April 14, 2023Vol.49 No.15
In Brief UC Davis CCC receives first SPORE grant for immunotherapy in head and neck cancer April 14, 2023Vol.49 No.15
In Brief James P. Allison awarded Block Memorial Lectureship at The Ohio State April 14, 2023Vol.49 No.15
In Brief Francisco Sanchez-Vega awarded Health Equity Fellowship from Corning and MSKCC to explore disparities in cancer outcomes April 14, 2023Vol.49 No.15
